Premium
Phosphoramidate Prodrugs Deliver with Potency Against Hepatitis C Virus
Author(s) -
Mehellou Youcef
Publication year - 2010
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201000310
Subject(s) - phosphoramidate , prodrug , potency , virology , hepatitis c virus , pharmacology , chemistry , medicine , virus , stereochemistry , biochemistry , in vitro
INX‐08189: A new sensation! The hepatitis C virus (HCV) antiviral clinical candidate INX‐08189, which is a phosphoramidate prodrug of 2′‐ C ‐methylguanosine, has recently entered human clinical trials. This anti‐HCV nucleoside‐derived phosphoramidate, the third of its kind currently under clinical evaluation, has an impressive overall pharmacological profile and synergistic efficacy with other antiviral agents, and its development is highlighted here.